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Abstract. Sickle cell disease (SCD) is an extremely heterogeneous disease that has been
associated with global morbidity and early mortality. More effective and inexpensive therapies
are needed. During the last five years, the landscape of the pharmacotherapy of SCD has
changed dramatically. Currently, 54 drugs have been used or under consideration to use for the
treatment of SCD. These fall into 3 categories: the first category includes the four drugs
(Hydroxyurea, L-Glutamine, Crizanlizumab tmca and Voxelotor) that have been approved by
the United States Food and Drug Administration (FDA) based on successful clinical trials. The
second category includes 22 drugs that failed, discontinued or terminated for now and the third
category includes 28 drugs that are actively being considered for the treatment of SCD.
Crizanlizumab and Voxelotor are included in the first and third categories because they have
been used in more than one trial. New therapies targeting multiple pathways in the complex
pathophysiology of SCD have been achieved or are under continued investigation. The emerging
trend seems to be the use of multimodal drugs (i.e. drugs that have different mechanisms of
action) to treat SCD similar to the use of multiple chemotherapeutic agents to treat cancer.
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Introduction. Sickle cell anemia (SCA) is among the
most common inherited hemolytic anemias, and affects
an estimated 100,000 persons in the US and probably
millions worldwide.1 The true global incidence of
sickle cell disease (SCD) is unknown. The World
Health Organization has estimated that each year
220,000 babies are born with SCD in Africa, and that
SCD accounts for up to 16% of deaths of children aged
< 5 years in some African countries.2,3 The reported
prevalence of the sickle cell trait in African Americans
varies from 6.7 to 10.1% and in Africans the range is
from 10 to 40% across equatorial Africa and decreases
to between 1 and 2% on the North African coast and

< 1% in South Africa.4-6 The prevalence of the sickle
cell trait varies widely worldwide and may be as high
as 50% in certain regions.6-8 The prevalence of SCA is
~ 1 in 600 newborn African American infants and
150,000 - 300,000 newborn Africans.9-11
Sickle cell anemia is a hereditary disorder of
hemoglobin (Hb) where the sickle gene is inherited,
homozygously, from both parents. The sickle mutation
is the result of a single base change (GAG → GTG) in
the sixth codon of exon 1 of the β-globin gene
responsible for the synthesis of the β-globin
polypeptide of the Hb molecule (α2β2). This change, in
turn, results in replacement of a normal glutamic acid
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with valine at position 6 of the β-globin chain and the
formation of sickle Hb. Sickle erythrocytes are rigid
with decreased deformability and reduced life span
resulting in hemolysis, vaso-occlusive disease,
vasculopathy and subsequent inflammation and end
organ damage.12,13
Clinical manifestations of SCD include pain
syndromes, anemia and its sequelae, organ failure
including infection/inflammation and comorbid
conditions.14 The painful acute vaso-occlusive crisis
(VOC) is the hallmark of SCD and traditionally, has
been thought to be to be due to sickle erythrocytes
occluding the microvasculature, especially within
bones, and causing tissue ischemia, injury, and pain.
Recent studies, however, suggest that the mechanism is
a more complex process that is multicellular, involving
interactions with the vascular endothelium, as well as
contributions from hemolysis, inflammation, and
coagulation.15 Despite having a common genetic basis
and similar pathophysiology, individual patients with
SCA have a highly variable clinical phenotype. The
prevalence of these complications varies with age from
infancy through adult life as shown in Figure 1.
However, pain, infections and anemia requiring blood
transfusion occur throughout the life span of affected
patients.
Clinical care for affected individuals has been mostly
palliative,
including
supportive,
symptomatic,
preventative and abortive approaches, as shown in
Table 1.
Advances in the management of SCD beyond
palliation include pharmacotherapy and curative
cellular therapies. The latter include stem cell
transplantation and gene therapy15,16 and these will not

be addressed in this review. In addition, some of the
current approaches to the management of SCD could
be pharmacologic or nonpharmacologic, especially
when it comes to pain management. Examples of
nonpharmacologic treatments include meditation,
therapeutic massage, transcutaneous electrical nerve
stimulation, heat and cold packs, distraction, relaxation,
music, guided imagery, self-hypnosis, acupuncture and
biofeedback.13,17 Current examples of pharmacologic
therapies include the use of non-steroidal antiinflammatory drugs, opioids, adjuvants, steroids, and
so on.13 The aim of this study is to review the current
status of pharmacotherapy for the treatment of SCD,
Historically, pharmacotherapeutic drugs that have been
tried to treat SCD fall into three groups. The first group
includes the successful drugs approved by the FDA
shown in Table 2. The second group includes the drugs
that were tried but failed to show a beneficial effect
shown in Table 3. The third group includes potential
drugs that are being used in different phases of
randomized clinical trials shown in Table 4 and will be
discussed below.
The Economic Burdens of SCD. Sickle cell disease is
a global disease affecting millions of people worldwide
and hundreds of thousands in the US. It affects not only
those of African descent, but also persons of Middle
Eastern, Indian, Latin American and Mediterranean
descent. It has received very little attention and even
less research funding. National Institute of Health
(NIH) grants for sickle cell research were much less
than that for less-common inherited diseases. In 1972,
the National Sickle Cell Anemia Control Act was
signed, which paved the way for more research funding

Figure 1. Sequence of complications of sickle cell anemia from birth through adult life. ACS = acute chest syndrome; AVN = Avascular
necrosis; CVA = Cerebrovascular accident. From Hem Onc Clin North Am. 2005; 19:785-802. Used with permission.
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Table 1. Palliative Management of Sickle Cell Disease and its Complications.
Management

Definition
Management intended to maintain the essential requirements for good health
1. Supportive
such balanced diet, sleep, hydration, folic acid, etc.
Management targeted to alleviate the symptoms of the disease as they occur.
2. Symptomatic
These include blood transfusion for symptomatic anemia, analgesics for
pain, antibiotics for infections, etc.
Approaches to prevent the occurrence of complications of the disease. These
3. Preventative
include things like vaccination, avoidance of stressful situations, transfusion
to prevent the recurrence of stroke, etc.
Major purpose of this approach is to abort painful crisis thus preventing
4. Abortive
them from getting worse or precipitating other complications. Nitric oxide
aborted VOCs in the ED but not during hospitalization.
Adapted from Blood. 2012;120(18):3647-56. Used with permission.
Table 2. Approved Drugs.
Compound

Company

Hydroxyurea

Structure

Mechanism of Action

Hydroxycarbamide
CH4N2O2

An antineoplastic agent
that inhibits DNA
synthesis through the
inhibition of
ribonucleotide
diphosphate reductase.
Hb F Induction,
reduces inflammation
and hemolysis

Numerous

2-Amino-4-carbamoylbutanoic acid
L-Glutamine
(Endari)

Emmaus
Medical Inc.

Crizanlizumabtmca

Novartis

Monoclonal antibody

Formulations
Capsules: Hydrea and
Droxia; 100, 200, 300,
400, 500 mg
Tablets: Siklos;100
mg, 1000 mg
Solution 100 mg/ml or
higher as needed

Not well known. It may
improve the NAD
redox potential in
sickle RBCs through
increasing the
availability of reduced
glutathione.

Powder in packets
containing 5g each

Anti-P-selectin

Intravenous solution

Benzaldehyde, 2-hydroxy-6-((2-(1-(1methylethyl)-1H-pyrazol-5-yl)-3pyridinyl)methoxy)

Voxelotor
(Oxbryta,
GBT440)

Global
Blood
Therapeutics
Inc

Hb S Polymerization
inhibitor

Tablets (500 mg) for
oral use

Indication

Sickle cell
anemia;
Myeloproliferative
disorders, certain
cancers

Reduction of the
acute
complications of
sickle cell disease
in adult and
pediatric patients
5 years of age and
older
Reduces the
frequency of
VOCs in adults
and pediatric
patients aged 16
years and older

Treatment of
sickle cell disease
in adults and
pediatric patients
12 years of age
and older

NAD = nicotinamide adenine dinucleotid.

and established screening and education programs. The
NIH dedicated $10 million to be spent on SCD
research at that time.13 The economic burden to
patients with SCD is significant.18-22 Many patients are
living in poverty with their illness due to chronic pain,
and physical disability limiting their ability to work
and contribute to society.13 The economic burden on

society was estimated at $1.1 billion in 2009.18 This
number is projected to increase as patients with SCD
are living longer as we continue to improve supportive
care. A solution to this problem is not simple, requiring
multidisciplinary action with increased funding,
legislation, research and supportive services. Simple
therapy with hydroxyurea (HU) is still not available to
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Table 3. Completed multicenter randomized double-blind placebo-controlled trials to prevent or treat sickle painful crises that failed,
discontinued or terminated.
Compound

Company

Acetylsalicylic acid

Takeda

AES-103

Dipyridamole

Indication
General pain and thrombosis,
SCD

AesRx

Anti-sickling agent

Anemia; SCD

Boehringer Ingelheim
Pharmaceuticals, Inc

RBC hydration

Thrombosis; SCD

Oxide

Stage of Development
Phase I and II study for SCD
completed
Phase I study for SCD
completed. Phase II study for
SCD terminated by the
Sponsor due to unbinding
between study drug and
placebo groups at the subject,
site and Sponsor levels

HemaQuest

γ globin gene promoter

Ikaria

Vasodilator

Therapeutic for VOC

Phase III for SCD; Failure

[7]

Ceased; Phase I for SCD

[8]

Phase II for SCD terminated
due to slow accrual and no
cost extension not approved
by NHLBI

[6]

Vasodilator

Magnesium
(MgSO4)

Numerous companies
produce magnesium
as
magnesium oxide,
magnesium citrate,
magnesium sulfate,
magnesium gluconate
and magnesium
pidolate

RBC hydration
Therapeutic agent

Vitamin
VOC

Sangart

Prevents
microvascular stasis;
Therapeutic agent

Anemia; Treat SCD

Oxirane, methyl-,
polymer with oxirane,
block, Therapeutic
agent

Surfactant

Glaxo Smith Kline

Anti-inflammatory
agent

Phase II for SCD terminated
due to manufacturing problem
with study drug

Eli Lilly

Inhibition of platelet
activation and
aggregation

Improves several
cardiovascular risk factors:
lowers serum triglyceride
concentration, lowers blood
pressure, reduces resting heart
rate, improves endothelial
dysfunction; SCD
Prevention of VOC

Failure

Pfizer

Gardos channel
blocker, Preventive
agent

Prevention of VOC

Phase II completed for SCD;
Drug increased red cell
survival and hematocrit and
blood viscosity; Phase III trial
failed

Preventive agent

Prevention of VOC

Failure

Used to treat cyanide
poisoning,
Therapeutic agent for
leg ulcers

Vasodilator; treat SCD leg
ulcers

Phase I and II study for SCD
terminated due to low
enrollment

Omega-3-acid
esters

ethyl

Prasugrel (DOVE Trial)

Senicapoc

CytRx

Sildenafil
Sodium nitrite

Hope

supplement;

Treat
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[5]

Phase II for SCD terminated

Asklepion

Nonionic
polyoxyethylenepolyoxypropylene;
Poloxamer 188 (Flocor)

[2,3]

[4]

L-citrulline

MP4CO

[1]

Phase II study withdrawn

Pediatric pulmonary
hypertension, postcardiopulmonary bypass
surgery; SCD

Sulfate

Reference

Acute myocardial infarction,
unstable angina, abrupt closure
following coronary
angioplasty, stroke and other
diseases
associated with arterial
thrombosis; treat VOC
SCA and β-Thalassemia

Antiplatelet agent
Use as therapeutic
agent for VOC

Millennium and
Schering
Plough

Eptifibatide

HQK 1001
Inhaled Nitric
(NO)

Mechanism of Action
Benzoic acid, 2(acetyloxy)-

[9]

Phase II and III for
SCD; Failure

Discontinued; Phase I
completed. Phase II
withdrawn prior to enrollment
for SCD
Treat VOCs and ACS in SCD
and acute
myocardial infarction

[10,11]

[12-13]

[15,16]

[17]

[18,19]

[20, 21]
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[22]

TRF-1101

TRF Pharma

Varespladib sodium

Shionogi

Vepoloxamer 18 (EPIC)

Mast Therapeutics

Vorintostat

Merck & Co.

Sevuparin

Rivipansel
GMI-1070

Sanguinate

Modus therapeutics

sodium;

GlycoMimetics

Prolong
Pharmaceutical

Anti-sickling agent

Inhibitor of secretory
phospholipases A2
(sPLA2)
Similar to Poloxamer
188
Hb F induction
Polysaccharide‐based
drug that is designed to
retain the anti‐adhesive
properties of heparin.
Therapeutic agent
1,3,6Naphthalenetrisulfonic
acid, 8-[[13[(1R,3R,4R,5S)3-[[2-O-benzoyl-3-O[(1S)-1-carboxy-2cyclohexylethyl]-_-Dgalactopyranosyl]oxy]4-[(6-deoxya-Lgalactopyranosyl)oxy]5-[[(1,2,3,6tetrahydro2,6-dioxo-4
pyrimidinyl) carbonyl]
amino] cyclohexyl]Sanguinate is
PEGylated Bovine
Carboxyhemoglobin

SCD

Therapy for acute chest
syndrome in SCA

Phase I study completed and
successfully demonstrated
improved microvascular
blood flow in patients with
SCD and revealed no drugrelated side effects.
Phase II study terminated
due to perceived futility
because the baseline pain
score in first 40 patients was
too low to be able
demonstrate improvement.
Discontinued; no current
studies being conducted in
relation to SCD

[23]

[24]

Therapeutic for VOC

Failure

[25]

Cutaneous T-cell lymphoma;
SCD

Phase II terminated due to
slow accrual

[26]

Treatment of VOCs

Underwent Phase I and II
Trials. Failed to Show
Clinically Meaningful
Improvements in Managing
VOCs,

Inflammation and VOCs in
SCD.
Therapeutic agent

Designed to prevent clumping
of RBC and maintain blood
flow. Therapeutic agent

Phase III to treat VOC failed

[27]

[28,29]

Phase II trial to treat VOC
failed

[30]

NHLBI: National Heart, Lung, and Blood Institute; RBC = Red blood cell; SCA = Sickle cell anemia; SCD = Sickle cell disease; VOC:
Vaso-occlusive crisis.

the millions in Africa today. As we continue to push
for new therapies for SCD, HU continues to have
tremendous potential in the global marketplace.
Evolution of the Approaches to Treat SCD. Since
sickled cells were first described in 1910 and the
mutation causing abnormal Hb S was identified in
1949, the complex mechanism underlying its
pathophysiology continues to evolve.23 A cascade of
events driven by endothelial damage and inflammation
leads to vasculopathy. The inciting event is injury to
the red blood cell (RBC) membrane. Hemoglobin S
polymerization impairs deformability of the RBC and
causes oxidative injury and destruction of the RBC.
RBC injury exposes phosphatidyl serine and releases
Hb and other intracellular contents. This in turn
depletes NO, increases endothelial adherence, releases
proinflammatory cytokines and activates the

coagulation cascade causing ischemia, reperfusion
injury and vascular damage.12,17,23
Damaged sickle cells are prone to adhere to the
endothelium by adhesion molecules. The RBC
membrane receptors VLA-4/a4b1 bind to endothelial
receptors directly to vascular cell adhesion molecule 1
(VCAM-1) and interacts with subendothelial matrix
proteins (BCAM/LU, a4b1 with the laminin and von
Willebrand factor).24,25 Red blood cell interactions with
the vascular endothelium also lead to the production of
oxygen radicals by activating transcription factor
nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-kB). NF-kB upregulates the production of
endothelial adhesion molecules such as E-selectin,
VCAM-1 and intracellular adhesion molecule-1
(ICAM-1). P-selectin and E-selectin on endothelial
cells have been suggested to participate in.26,27
In preclinical studies an anti-P-selectin molecule
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Table 4. Potential drug therapies for the management of SCD.
Compound

Company

Structure

Indication

Stage of Development

Decitabine

Astex
Pharmaceuticals

5-aza-2’-deoxycytidine

Myelodysplastic
syndrome, SCD

Phase II study completed
for SCD

Sodium butyrate

Sigma Aldrich

C4H7NaO2

Inhibit
tumor
growth, SCD

Celgene
Corporation

C13H11N3O4

Panobinostat

Novartis

Intravenous Ig

GRIFOLS
BIOLOGICALS,
Inc.

(2E)-N-Hydroxy-3-[4-[[[2(2-methyl-1H-indol-3-yl)
ethyl]amino]methyl]phenyl]2-propenamide

Graft
versus
host
disease, myelofibrosis,
scleroderma
and
idiopathic pulmonary
Fibrosis, SCD

Low-molecular
weight heparin

Sanofi

(C26H40N2O36S5)n

Dalteparin

Pfizer

SelG1
(Crizanlizumab)

Selexys
Pharmaceuticals;
Now Novartis

2-O-sulpho-α-Lidopyranosuronic
acid
structure
at
the
nonreducing end and a 6-Osulpho-2,5-anhydro-Dmannitol structure at the
reducing end of their chain

Propranolol

Forest
Laboratories

Pomalidomide

C6332H9826N1692O1980S42

Humanized
antibody

P-selectin

2-Propanol,
1-[(1methylethyl) amino]-3-(1naphthalenyloxy)
1-(6-Amino-9-β-Dribofuranosyl-9H-purin-2yl)-N-methyl-1H-pyrazole4-carboxamide

Regadenoson:
Adenosine
2A
receptor
antagonist

Gilead Sciences

NKTT120

NKT
Therapeutics

Humanized
iNKT

Atorvastatin
Statins

FA Davis

(C33H34FN2O5)2Ca. 3H2O

Zileutin

Abbott
Laboratories and
now Cornerstone
Therapeutics
Inc.

C11H12N2O2S

N-acetyl cysteine

Galleon
Pharmaceuticals

L-Cysteine, N-acetyl
C5H9NO3S

Meda
Inc.

1,2-Dithiolane-3-pentanoic
acid
C8H14O2S2

α-Lipoic acid

Biotech

antibody

to

cell

Treatment of multiple
myeloma and other
cancers, SCD
Plasma
protein
replacement
Therapy, SCD
Deep vein thrombosis,
Myocardial infarction,
unstable angina, SCD

Acute
venous
thromboembolism, SCD

No current studies
being conducted in
relation to SCD

Mechanism of Action
DNA methylase
inhibitor; Hb F
induction
Hb F induction

Phase I study completed for
SCD

Hb F induction

Phase I for SCD

Hb F induction

Recruiting for Phase I/II for
SCD

Inhibits cellular
adhesion

Phase II for SCD

Inhibits cellular
adhesion

Phase II completed for SCD

Inhibits cellular
adhesion

VOCs in children and
adults with SCD

Sustain Trial Phase II
completed for VOC; Four
other trials are ongoing

Inhibits cellular
adhesion

Hypertension, SCD

Phase II completed for SCD

Inhibits
adhesion

Vasodilator

Phase II completed for SCD

Rapid and sustained
iNKT cell depletion in
adults with SCD

Phase I study for SCD
completed

Improves
endothelial
dysfunction in SCD with
nephropathy

Phase II trial has just been
completed

Approved
for
the
prophylaxis
and
treatment of chronic
asthma for patients who
are
age
12
and
older. Beneficial in SCD
animal model
Rad/chemotherapyinduced
mucositis;
Radio/chemotherapy
induced injury, bone
marrow,
thrombocytopenia;
apnea, SCD
Diabetic
SCD

neuropathy,

for

SCD

In an open randomized trial,
the ALA dose used was not
effective
to
prevent
oxidative
damage
in
patients with SCD
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Anti-inflammatory
Agent
Reduce
chronic
inflammation associated
with SCD
3-hydroxy-3methylglutarylcoenzyme A (HMGCoA)
reductase
inhibitor
Inhibits 5- lipoxygenase,
a potent inflammatory
leukotriene

Phase I trial completed

Phase
III
completed

cellular

Anti-inflammatory
Agent,
reduces
oxidative stress in sickle
cell patients

Anti-inflammatory and
anti-oxidant agent
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Canakinumab

Ambrisentan

Novartis

Augusta
University with
Gilead Sciences
and NHLBI as
collaborators

Rivaroxaban

Bayer

Arginine

Numerous
companies
since
produce
this is a vitamin
supplement

Inhaled
Nitrix
Oxide (NO) in the
ED

INO
Therapeutics

PF 04447943

Pfizer

IMR-687

Imara Inc

Canakinumab
is
a
recombinant, human antimonoclonal
human-IL-1β
antibody that belongs to the
IgG1/κ isotype subclass

Endothelin
antagonist (ERA)

Receptor

5-Chloro-N-({(5S)-2-oxo3-[4-(3-oxomorpholin-4yl)phenyl]-1,3-oxazolidin-5yl}methyl)
thiophene-2carboxamide
2-Amino-5
guanidinopentanoic acid

6-[(3S,4S)-4-methyl-1(pyrimidin-2ylmethyl)pyrrolidin-3-yl]-1(tetrahydro-2H-pyran-4-yl)1,5-dihydro-4Hpyrazolo[3,4-d]pyrimidin4-one
6-[(3S,4S)-4-Methyl-1-(2pyrimidinylmethyl)-3pyrrolidinyl]-3-(tetrahydro2H-pyran-4-yl)imidazo[1,5a]pyrazin-8(7H)-one

For
Familial
Cold
Autoinflammatory
Syndrome
(FCAS),
Muckle-Wells
Syndrome (MWS) and
SCD

Phase II ongoing

Anti-inflammatory

Determination of its
safety and tolerability in
treating SCD

Phase I

Anti-inflammatory,
analgesic and improves
pulmonary blood low

For
treatment
of
thrombosis
including stroke, prevent
VOC

Phase I for SCD completed

Direct
oral
coagulant

Phase III study for SCD
completed in Brazil. Phase
II study for SCD completed
in US. Another Phase II
study for SCD is recruiting
in the US.

Vasodilatation

Chest pain, high blood
pressure and peripheral
arterial disease, SCD

Therapeutic for VOC in
the ED

double-blind, randomized,
placebo controlled clinical
trial

Evaluate change from
baseline in potential
SCD-related biomarkers

Phase 1b for patients with
SCD completed

SCA
(Homozygous
HbSS
or
Sickle-β0
Thalassemia)

Phase 1a completed. Phase
2a is recruiting with an
open extension study

Molecular formula C21 H26
N6 O2

Riociguat

Bayer

Oinciguat
(IW-1701)

Ironwood,
Cyclerion
Therapeutics

Voxelotor (GBT440)

Global
Blood
Therapeutics Inc

Methyl 4,6-diamino-2-[1-(2fluorobenzyl)-1H-pyrazolo
[3,4-b]pyridin-3-yl]-5pyrimidinyl(methyl)
carbamate

OlinciguatUNIIPD5F4ZXD2
C21H16F5N7O3

Benzaldehyde, 2-hydroxy-6((2-(1-(1-methylethyl)-1Hpyrazol-5-yl)-3pyridinyl)methoxy)

Multicenter study
patients with SCD

in

Phase
2
multi-center,
randomized, double-blind,
placebo-controlled, parallel
groups study. Recruiting

Patients with SCD

STRONG SCD to evaluate
the safety and tolerability of
different dose levels in
SCD patients. Recruiting

Prevention of VOCs and
treatment
of
other
complications

After successful phase I and
II trials, Phase 3 HOPE trial
Voxelotor
significantly
increased
Hb
levels
compared to placebo and
reduced
markers
of
hemolysis.
Exploratory
post-hoc trial showed that
Voxelotor
resolved
or
improved leg ulcers in
some patients.
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anti-

Vasodilatation

Vasodilatations;
Phosphodiesterase
inhibitor

9A

Phosphodiesterase
inhibitor
with
multimodal mechanism
of action:
Vasodilatation
Inhibition of white
blood cell adhesion
Increase Hb F level
Riociguat is a stimulator
of soluble guanylate
cyclase
(sGC),
an
enzyme
in
the
cardiopulmonary system
and the receptor for NO
resulting
in
vasodilatation
Stimulates
guanylate
cyclase (sGC), known to
play a key role in the
production of nitric
oxide. Vasodilatation

Inhibition of Hb S
polymerization.
Increases the affinity of
Hb S to oxygen
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FT-4202
Pyruvate Kinase
Activator (PKR)

Niacin
B3)

(Vitamin

Cholecalciferol
(Vitamin D3)

Forma
Therapeutics,
Inc.; Medpace,
Inc.

AbbVie Ltd

Numerous
companies

An oral small-molecule
agonist of pyruvate kinase
red blood cell isozyme
(PKR)

Treatment of hemolytic
anemias

Phase I

Agonist of pyruvate
kinase enzyme

C6NH5O2

Reduces risk of heart
disease, improves blood
flow in people with SCD

Phase II study completed
for SCD

Increases levels of HDL
and improves blood
flow

25-Hydroxyvitamin D3

Vitamin
SCD

supplement,

Phase study with adult
patients
with
SCD
completed. Phase I and II
completed
with pediatric patients with
SCD. Phase III for pediatric
patients with SCD not yet
recruiting

Supplementary vitamin

ADP: Adenosine diphosphate; ED = Emergency department; Hb: Hemoglobin; HDL = High-density lipoproteins; kDa: Kilodalton; NO:
Nitric oxide; RBC: Red blood cell; SCA: Sickle cell anemia; SCD: Sickle cell disease; VOCs: Vaso-occlusive crises.

showed increased microvascular flow and reduced
adhesion of leukocytes to the endothelium.26 ICAM-4,
another RBC membrane protein, which participates in
adhesion, can be activated by epinephrine to adhere to
endothelial membrane and exacerbate vaso-occlusive
disease and also increased leukocyte adhesion to
endothelium.27 When treated with propranolol (a badrenergic receptor antagonist) VOCs were
diminished.28,29
In addition to adherence to endothelial cells, RBCs
in SCA also adhered strongly to leukocytes in VOCs
via interactions with P-selectin and E selectin. This
interaction is propagated by TNF-a. Selectins function
in adhesion to the vessel wall by recruiting rolling
particles and cells and also contribute to cell activation.
Patients with SCD have chronic elevation of
proinflammatory cytokines at baseline, including Creactive protein, TNF, IL-1 and IL-8. Damaged RBCs,
activated endothelial cells, leukocytes and platelets
(PLTs) contribute to a proinflammatory environment.
Sickled RBCs stimulate endothelial cells to release
TNF-α and IL-1β. There is increased production of
placental growth factor, which activates monocytes to
release reactive oxygen species (ROS), which enhances
inflammation.
Additionally, invariant natural killer T (iNKT) cells
are activated in patients with SCD, suggesting that
iNKT cells may play a critical role in mediating
inflammation. Intravascular hemolysis results in
release of cell-free Hb in plasma, and hemin release
that contribute to the inflammation.25,30 Nitric oxide
(NO) is produced by the endothelium from arginine
and causes vasodilation by binding to endothelin-1, a
vasoconstrictor. Intravascular hemolysis releases Hb,
which scavenges NO in the plasma and subendothelial
spaces.
Depletion of NO leads to vasoconstriction and
formation of ROS. Nitric oxide also downregulates
adhesion molecules, VCAM-1, ICAM-1 and E-selectin.
Erythrocyte arginase released during hemolysis

decreases arginine levels and decreases NO production.
The byproducts of these reactions, urea, proline,
polyamines and free radicals, cause vascular
remodeling and vasculopathy. Patients with SCD have
elevated asymmetric dimethylarginine, which inhibits
arginine transport and promotes endothelial
dysfunction.17,31,32
These inflammatory processes activate the
coagulation cascade. Phosphatidylserine expression on
RBC surface and microparticles activates tissue factor
and, in turn, the extrinsic coagulation cascade. Tissue
factor also promotes inflammation and endothelial
damage. In preclinical studies in transgenic sickle mice,
lowering tissue factor levels resulted in lower plasma
levels of IL-6 and soluble VCAM-1.33 Sickle cell
disease is a chronic inflammatory state and ROS are
increased at baseline compared with normal controls.
Hemolysis releases Hb, and iron products, which
increase ROS that generate superoxide (O2-) and
peroxynitrate (ONOO-), which promotes an
inflammatory response and causes cell death. Patients
with SCD have impaired buffer system with decreased
glutathione, and other antioxidants.34-36
Approved Pharmacotherapeutic Drugs. The ideal
drug for SCD would have analgesic properties, be able
to prevent VOCs or abort them with a rapid onset of
action, would decrease the severity and frequency of
VOCs, have limited hazardous side-effect profile and
be effective in all patients, and available globally.
Currently HU, L-glutamine, Crizanlizumab tmca and
Voxelotor shown in Table 2, are the only agents that fit
some of these criteria and are approved by the FDA.
Hydroxyurea. Hydroxyurea has many qualities of the
ideal drug for SCD. It was first synthesized in 1869
and used in myeloproliferative disorders. Chemically it
is a synthetic urea analog; also referred to as
hydroxycarbamide (HC) that functions as an
antineoplastic agent. In this review HU and HC are
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used synonymously. There is seemingly a tendency to
use the HU acronym in the US and HC acronym in the
UK. Hydroxyurea was identified as a potent Hb F
inducer and was subsequently found to be both a
feasible and effective treatment option for SCA.13 It
decreases the frequency of VOCs, acute chest
syndrome (ACS), and the frequency of blood
transfusion. In addition, HU improves the quality of
life and decreases mortality in patients with SCA.37
However, HU is not effective in about 25% of those
with SCA, an acronym that also includes sickle-β0thalassemia (S-β0-T).38 Currently, it was found to be
teratogenic and possibly carcinogenic in animal
studies39 but not in humans so far. It was the first
pharmacotherapeutic drug to be approved by the FDA
and by the European Medicines Agency (EMA) for the
treatment of SCA.
Hydroxyurea is cell cycle specific for the S phase
and inhibits DNA synthesis as a ribonucleotide
reductase inhibitor. It induces the production of Hb F
in the majority of patients with SCA who are compliant
with therapy and thus prevents the formation of Hb S
polymers.
The molecular mechanisms by which HU induces
Hb F production are not fully clear. Proposed
mechanisms include selectively killing cells in the bone
marrow, and increasing the number of early erythroid
progenitors such as fetal erythroblasts that lead to
production of Hb F. It also reduces the number of
adhesive reticulocytes40 and circulating inflammatory
cells such as monocytes and neutrophils. It alters
circulating monocyte subsets and dampens the
inflammatory potential of SCD.41,42 It also improves
RBC deformability.43 More recently, HU was reported
to have antioxidant activity.44 It appears that patients
whose high neutrophil and reticulocyte counts decrease
significantly after HU therapy have a higher increase in
Hb F levels.3,21,45 In addition, HC affects the plasma
proteome of children with SCA resulting in reduced
inflammation and decreased activation of the
coagulation factors.46 The increased Hb F induced by
HU decreases the biomarkers of oxidative stress and
the scavenging of NO in both sickle cell mice and in
patients with SCD.44,47,48
More complex effects of HU involve the
production of NO, guanylyl cyclase and cGMP
dependent protein kinase pathway important in
inducing expression of the γ-globin gene. Additionally,
HU improves erythrocyte deformability, lowering of
circulating leukocytes and reticulocytes, and reduces
hemolysis.3,49,50 Since its first clinical application
reported in 1984 by Platt et al., many trials were
performed.51 The Multicenter Study of HU in SCA, a
placebo-controlled randomized Phase III trial of 299
adults with severe SCA, terminated early due to
significant reductions in frequency of VOC, ACS, need
for blood transfusion and delayed onset of first

VOC.52,53 This study led to the FDA approval of HU
for therapy on February 25, 1998 for moderately or
severely affected adults with SCA. The Pediatric
Hydroxyurea Phase III Clinical Trial (BABY HUG),
involving infants with SCA randomized either to HU
(fixed dose 20 mg/kg/day) or placebo. This trial
showed that HU did not clearly prevent organ damage,
the primary endpoint of the 2-year treatment period,
but significantly decreased the secondary endpoints:
pain, ACS, hospitalizations, and transfusions in
children.54-59
Formulations of HU are shown in Table 2. It is
available as capsules or tablets. Solutions of 100 mg/ml
or higher can be prepared by pharmacist as needed.60
The usual staring dose is 15 mg/k/day. This may be
increased gradually every month as needed to achieve
the maximum tolerable dose. Some providers maintain
a dose that increases Hb F to a desirable level before
achieving the maximum tolerable dose.
The common side effects of HU are listed in Table
5. Toxic effects are dose and time dependent and can
be prevented by careful monitoring and surveillance.
Side effects are generally reversible with cessation or
decrease of the drug dose. Hydroxyurea is
myelosuppressive and leukopenia is the most common
manifestation followed by thrombocytopenia and
anemia. Macrocytosis is common and may mask folic
acid deficiency, so folic acid supplementation is
recommended during treatment with HU. Idiosyncratic
side effects are rare, reversible and more common in
generic formulations.61 Figure 2 shows an example of
HU-induced melanonychia.
Phase IV of the HU study which refers to its use in
the general population post-approval by the FDA,
showed a plethora of publications globally addressing
various aspects of its pros and cons. Most important
among these are as described below.
a.
Adherence to HU Therapy. The BABY HUG
trial, which demonstrated safety and efficacy of
Table 5. Side Effects of Hydroxyurea.
Myelosuppression
Leukopenia/Neutropenia
Thrombocytopenia
Anemia
Megaloblastic Erythropoiesis
Idiosyncratic
Nausea, Vomiting
Stomatitis, Anorexia, Diarrhea
Constipation
Skin rash Erythema, Pruritus
Hair Loss
Hyperpigmentation, horizontal & Longitudinal
Melanonychia
Decreased Libido
Partial complex seizure
Long Term Effects
Unknown
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Figure 2. Fingernails of a 38-year-old man with sickle cell anemia and hydroxyurea-induced melanonychia characterized by longitudinal
(blue arrow) and diffuse (red arrow) bands. From J Blood Disorders Transf. 2013;4:5. Used with permission.

starting HU in infancy contributed to a robust increase
in HU prescribing for children with SCD.62
Hydroxyurea use in infants 5-12 months old resulted in
a better response compared with use in older patients.63
Moreover, prospective longitudinal follow-up of
children with SCD treated with HU since infancy was
highly effective in preventing complications of SCD.64
Pediatric hematologists strongly recommend the use of
HU in children with SCD early and frequently.65
Unfortunately, access to specialist care for
adolescents and adults with SCD is limited and
associated with many barriers. Most important among
these include appointment non-adherence.66 Factors
that seem to influence these barriers may be provideror patient-related. Thus, patients who felt their
providers were not listening to their concerns tended to
be non-adherent to HU therapy.67
Similarly, at the global level the use of HU for the
treatment of patients with SCD varied considerably.
The universal administration of HU to children with
SCD was successful in Malawi68 but not in Nigeria69
where concerns about its long-term safety and toxicity
limited its prescription by physicians and acceptability
by patients. The major barriers to the use of HU in the
treatment of SCD in Nigeria included lack of national
guidelines for the use of HU, concerns for infertility

and safety profile of HU in pregnancy and lactation.69
b.
Hydroxyurea and Stroke. According to the
Cooperative Study of SCD (CSSCD), stroke occurred
in 11% of children with SCA younger than 20 years of
age and 24% of adults by the age 45.70 However, the
use of transcranial Doppler (TCD) in the Stroke
Prevention in SCA (STOP 1) trial to identify persons at
higher risk for ischemic stroke, along with the
prophylactic management of those patients with
chronic transfusion (simple or RBC exchange), has
dramatically reduced the incidence of childhood
primary stroke to 2% to 3%.71,72 The STOP 2 trial
determined that regular transfusion for primary stroke
prevention could not be halted safely, even in patients
with a normal magnetic resonance angiogram whose
TCD results have normalized.72,73
Discontinuation of transfusions after 30 months
resulted in a high rate of reversion to abnormal TCD
velocity and stroke.72,73 A number of studies indicate
that transfusion to prevent the recurrence of strokes
should be performed indefinitely, even after transition
to adult programs.74-76 The advent of HU raised the
possibility if it could replace or decrease the need for
transfusion to prevent the recurrence of stroke.
However, the Stroke with transfusions changing to HU
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(SWITCH) trial and the Transcranial doppler with
transfusions changing to HU (TWITCH) trial were not
successful 77,78 and blood transfusion and iron chelation
therapy remain the better choice for the prevention of
primary and secondary stroke in patients with SCA.
Nevertheless, HU treatment of children with SCA is
associated with more intact brain white matter integrity
by using quantitative MRI79 and prevents the
conversion to abnormal transcranial doppler in SCA.80
The NIH guidelines for the management of SCD
indicated that if it is not possible to implement a
transfusion program in children and adults who have
had a stroke, then HU therapy is recommended.38
c.
Hydroxyurea and Leg ulcers. The effect of HU
on leg ulcers in patients with SCD is controversial,
though it has been reported to cause leg ulcers in
patients with myeloproliferative syndromes.81 Data on
leg ulcers from the Cooperative Study of Sickle Cell
Disease (CSSCD) identified five risk factors associated
with leg ulcers in patients with SCD.82 Leg ulcers were
more common in males and older patients and less
common in patients with α-gene deletion, high total Hb
level and high levels of Hb F. Since HU is known to
increase total Hb level and Hb F, one would expect that
HU would be protective against the development of leg
ulcers. Nevertheless, there are anecdotes of leg ulcers
occurring after therapy with HU and of healed old
ulcers reactivated after HU therapy.83 de Montalembert
et al followed a cohort of 101 children with SCD
treated with HU for a median of 22 months; among
these only one 18 year-old patient had leg ulcers 23
months after treatment.84
d.
Hydroxyurea: pregnancy and lactation. The
FDA developed a system to rate medications and drugs
based on potential benefits and risks to the fetus. Drugs
are classified into pregnancy categories A, B, C, D, and
X where A is safe and X contraindicated. Hydroxyurea
is classified as a category D drug; these drugs have
positive evidence human fetal risk but use may be
justified in some circumstances. Because HU, an Sphase antineoplastic drug, is known to be carcinogenic,
mutagenic, and teratogenic in animals, a major
inclusion criterion in the Multicenter Study of HU in
SCA (MSH) was the use of contraceptives both by
females and males, to avoid fetal exposure to HU.
Despite this precautionary measure, some women have
become pregnant while they or their male partners
were taking HU. Surviving patients enrolled in the
original MSH trial for up to 17 years post
randomization were followed.37 The findings suggested
that exposure of the fetus to HU did not cause
teratogenic changes in those pregnancies that
terminated in live birth, whether full term or
premature.39 This appears to be true whether the parent
taking HU was the mother or the father. Safety of HU

during pregnancy and SCD was also reported in 3 other
patients.85,86 Safety of HU during pregnancy was also
reported in other hematologic disorders.86
The NHLBI evidence-based SCD guidelines identified
the safety of HU during gestation and subsequent
lactation as an important knowledge gap that requires
further investigation. A clinical trial for that purpose is
underway.87
Similarly, breastfeeding is usually contraindicated
during maternal therapy with antineoplastic drugs, but
the evidence of this recommendation for HU is very
weak.38,88 Current recommendations state that
breastfeeding should be avoided for at least 3 hours
after the mother takes HU.89 Currently, clinical trial
[NCT02990598]: Hydroxyurea Exposure in Lactation
A Pharmacokinetics Study (HELPS) (HELPS) is
underway to examine the pharmacokinetics and
distribution of oral HU when administered as a single
dose to lactating women.90
L-Glutamine (Endari). L-glutamine is an amino acid
used in the synthesis of protein. It is the most abundant
amino acid in human blood.91 The body can usually
synthesize sufficient amounts of L-glutamine, but in
some instances of stress, the body's demand for
glutamine increases, and glutamine must be obtained
from the diet. Accordingly, it is a non-essential and
conditionally essential amino acid in humans. Reduced
glutathione is the primary buffer for reactive oxygen
species (ROS).
L-glutamine is metabolized to glutamate, the
glutathione precursor, and preserves intracellular
nicotinamide adenine dinucleotide (NAD), which is
necessary
for
glutathione
recycling.
Oral
supplementation of glutamine in SCD increases the
NAD redox potential and may reduce sickle
erythrocyte adhesiveness.32,33 Decreased NAD redox
potential due to low level of L-glutamine was a major
mechanism for the presence sickle RBCs under oxidant
stress conditions.92 Oral glutamine was developed by
Emmaus Medical for the treatment of short bowel
syndrome and in SCA and β thalassemia. It decreases
the resting energy expenditure in children with SCD. A
multicenter Phase III trial of L-glutamine
supplementation in 230 children to prevent VOC is
completed; results wed that the median number of pain
crises over 48 weeks was lower among those who
received oral therapy with L-glutamine, administered
alone or with HU, than among those who received
placebo, with or without HU.92-95 Two Phase II trials
are also completed.96,97
Endari was approved by the FDA on July 7, 2017 to
reduce the acute complications of SCD in adult and
pediatric patients 5 years of age and older.98 It is
available as an oral powder: 5 grams of L–glutamine as
a white crystalline powder in paper-foil-plastic
laminate packets. It should be administered orally,
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twice per day at the dose based on body weight as
follows: 5 g twice daily for patients weighing < 30 Kg,
10g twice daily for patients weighing 30-65 Kg and 15
g twice daily for patients weighing > 65 kg. Side
effects of Endari included low-grade nausea,
noncardiac chest pain, fatigue, and musculoskeletal
pain occurred more frequently in the l-glutamine group
than in the placebo group. There are no available data
on Endari use during pregnancy and lactation.
The efficacy of L-Glutamine in the management of
SCD awaits the data generated in phase IV post
approval in the general population of patients with
SCD.
Crizanlizumab tmca (ADAKVEO). The efficacy of
SelG1 (Crizanlizumab), a humanized anti-P-selectin
monoclonal antibody, in preventing VOCs was
evaluated in Phase II SUSTAIN trial in combination
with or without HU.99 Crizanlizumab intravenous
therapy resulted in a significantly lower rate of sickle
cell-related VOCs than placebo and was associated
with a low incidence of adverse events.99 The FDA
approved crizanlizumab-tmca (ADAKVEO, Novartis)
on November 15, 2019 to reduce the frequency of
VOCs in adults and pediatric patients aged 16 years
and older with SCD.100 The recommended dose is 5
mg/kg intravenously over a period of 30 minutes on
week 0, 2, and every 4 weeks thereafter. The most
common side effects (>10%) were nausea, arthralgia,
back pain, and pyrexia.
Voxelotor (Oxbryta, GBT440). Voxelotor is an
inhibitor of Hb S polymerization indicated for the
treatment of SCD in adults and children 12 years of
age and older. It exerts its action by biding to the
amino acid terminal of both α chains of Hb. The
efficacy and safety of Voxelotor (OXBRYTA) in SCD
was evaluated in a Phase III randomized, double-blind,
placebo-controlled multicenter trial in combination
with and without HU (HOPE Trial).101,102 It was
approved by the US FDA on November 19, 2019.103
The approval was accelerated based on increase in Hb.
Continued approval for this indication may be
contingent upon verification and description of clinical
benefit in confirmatory trial(s).
Efficacy was based on Hb response rate defined as a
Hb increase of >1 g/dL from baseline to Week 24 in
patients treated with OXBRYTA 1,500 mg versus
placebo. The response rate for OXBRYTA 1,500 mg
was 51.1% (46/90) compared to 6.5% (6/92) in the
placebo group (p < 0.001).
Recommended dosage of OXBRYTA is 1,500 mg
orally once daily with or without food. Recommended
dosage for severe hepatic impairment is 1,000 mg
orally once daily with or without food. The daily dose
of OXBRYTA has to be adjusted in the presence of
concomitant medications. Thus, in the presence of

strong CYP3A4 inhibitors or fluconazole, the dose
should be decreased to 1000 mg once daily. On the
other hand, in the presence of strong or moderate
CVP3A4 inducers the recommended dose should be
increased to 2,500 mg once daily.103
Pending Pharmacotherapeutic Drugs for the
Treatment of SCD. Currently, there are at least 50
unapproved pharmacotherapeutic drugs that were or
are being used or tried to treat SCD during the last two
decades. Most of these were multicenter randomized
double-blind placebo-controlled trials to prevent or
treat sickle painful VOCs. Preventive pharmacotherapy
includes drugs that are taken routinely as outpatients
with the hope that may decrease the frequency of
VOCs that require treatment in the emergency
department or hospital. Therapeutic pharmacotherapy
includes drugs that are administered after admission to
the hospital with the hope that they may abort the VOC
and decrease the length of hospital stay and the amount
of analgesics used. Twenty-two of these drugs, shown
in Table 3, failed, discontinued or terminated.
Among the 22 drugs listed in Table 3, Rivipansel
sodium (GMI-1070), has an interesting history that
demonstrates the steps a drug has to go through in
order to achieve approval. It is a small-molecule panselectin inhibitor that binds to E, P and L selectin that
was developed by Glycomimetic to target
inflammation in sickle VOCs. It improves blood flow
by inhibiting E-selectin and neutrophil activation. A
randomized, double-blind, placebo-controlled Phase II
trial in 76 subjects hospitalized for sickle cell VOC
assessing GMI-1070 is complete. Data showed that the
patients treated with rivipansel sodium experienced
reduction in duration of VOC, length of hospital stay
and reduction in the use of opioids for pain relief. Both
adult and pediatric patients demonstrated improvement
and adverse event rates were comparable between
rivipansel sodium and placebo.104,105 However, Phase
III of the study failed.
Failure of the 22 drugs listed in Table 3 teaches us
at least two important lessons. First, most of the drugs
that went through phase III trials failed to treat or abort
VOCs or ACS. The approved drugs prevented or
decreased the frequency of VOCs. The second lesson is
that hydration of sickle RBC does not seem to be an
adequate approach in the management of SCD. In the
last 2-3 decades hydration of sickle RBC was one of
the major approaches to treat SCD. The phase III
Senicapoc trial showed that hydration of sickle
erythrocytes is counterproductive. This study
concluded that hydration of sickle RBC improves their
survival which, in turn, increases the blood hematocrit.
Consequently, higher hematocrit is associated with
increased blood viscosity that promotes vaso-occlusion
and the precipitation of a new VOC.
The remaining 28 drugs that are not approved by the
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FDA so far but are being used in different stages of
clinical trials to prevent or treat VOCs are listed in
Table 4 and discussed below. The mechanism of action
of these drugs includes Hb F induction, inhibition of
cellular adhesion, anti-inflammatories, surfactants,
anti-platelets, vasodilators, anti-adhesives, inhibition of
Hb S polymerization, etc. It is rather unfortunate that
the majority of these drugs as well as HU were
developed for indications other than SCD. This is
unlike other rare diseases such as hemophilia and
cystic fibrosis for which a few, if any, repurposed
drugs are used. The reasons for this disparity are not
known. The complex pathophysiology of SCD, its
protean clinical manifestations and the suboptimal
interest from funders and scientists may be some of the
reasons.
Potential Pharmacotherapeutic Drugs for the
Treatment of SCDl.
a.
Targeting Hb F production: Decitabine is an
intravenous cytosine analog 5-aza-2’-deoxycytidine,
which hypomethylates DNA by inhibiting DNA
methyltransferase. It is approved for treatment of
myelodysplastic syndrome. It increases fetal Hb by
reactivating
the
silenced
γ-globin
through
hypomethylation at its promoter site. In a small study
of eight patients refractory or intolerant to HU, it
increased Hb F and Hb levels when administered
subcutaneously.106 Ongoing trials will further clarify its
efficacy and tolerability. A Phase II study with planned
enrollment of 40 patients with high-risk SCD is
recruiting.107 A Phase I combination study of oral
decitabine with tetrahydrouridine,108 a competitive
inhibitor of cytidine deaminase, is also recruiting and
its aim is to evaluate oral bioavailability of decitabine
in combination therapy.109,110
Pomalidomide is an orally active thalidomide
analog developed by Celgene for the treatment of graft
versus host disease, SCA, myelofibrosis, scleroderma
and idiopathic pulmonary fibrosis. Preclinical studies
showed that it induced Hb F production in an SCD
model with similar efficacy as HU. Surprisingly,
pomalidomide improved erythropoiesis in comparison
to myelosuppression seen with HU. However, when
given in combination with HU, this effect was lost and
fetal Hb levels were suppressed.111 A Phase I study of
pomalidomide in SCD was completed. Twelve patients
enrolled and data have not been published.112
Panobinostat is a recently approved histone
deacetylase (HDAC) inhibitor.113 A study of
panobinostat in patients with SCD is active but not
recruiting yet.114 L-arginine, a substrate for NO, was
evaluated in combination with HU in a small
randomized trial of 21 adult patients with SCD. There
was a greater response in fetal Hb levels and
reticulocyte count in the group receiving combination
therapy versus HU alone. This study suggests that fetal

Hb synthesis depends on NO effect on erythroid
progenitors.115
b. Targeting adhesion: Intravenous Ig (IVIg) also
inhibits leukocyte adhesion and activation by binding
to FcγRIII expressed on neutrophils.116 A Phase I/II
trial is currently recruiting to evaluate Gamunex
(Intravenous gamma globulin) versus normal saline in
sickle cell acute pain.117
Low-molecular weight heparins (LMWH). In a
randomized clinical trial of 253 patients, Tinzaparin, an
LMWH, showed reduced duration of VOC and no
severe bleeding complications.118 These results need to
be validated in a multicenter study. A recent Phase II
trial of an oral P-selectin inhibitor (pentosan
polysulfate sodium) similar to heparin but with greater
P-selectin blocking ability than heparin showed
improved microvascular flow in SCD patients in a
Phase I study.119 Another LMWH, Dalteparin, was
used in a completed phase II trial.120
Crizanlizumab.
The
efficacy
of
SelG1
(Crizanlizumab),
a
humanized
anti-P-selectin
monoclonal antibody, in preventing VOC was
evaluated in five different trials. The first was the
successful SUSTAIN trial that was approved by the
FDA on November 15, 2019 as described above. The
remaining four trials are as follows:
• The STAND trial whose purpose is to compare the
efficacy and safety of 2 doses of crizanlizumab (5.0
mg/kg and 7.5 mg/kg) versus placebo in adolescent
and adult SCD patients with a history of VOCs
leading to healthcare visit.121
• The SPARTAN trial to evaluate the safety and
efficacy of crizanlizumab in SCD related
priapism.122
• Phase II CSEG101B2201 study is to confirm and to
establish the appropriate dosing and to evaluate the
safety in pediatric patients ages 6 months to <18
years with a history of VOC with or without HU,
receiving ranibizumab for 2 years. The approach is
to extrapolate from the PK/pharmacodynamics
already established in the adult population. The
study is designed as a Phase II, multicenter, openlabel study.123
• Phase II multicenter open label study to determine
the pharmacokinectics and pharmacodynamics
study of SEG101 (criznalizumab) in SCD patients
with VOCs.124
Propranolol significantly reduced RBC adhesion in
a dose-dependent manner. Adverse events were not
severe, did not vary with the dose administered and no
elevation in heart rate was noted. These results imply
that β-blockers have a potential role in inhibiting RBC
adhesion.125 A Phase II study of propranolol in SCD
has been completed and no data have been reported at
the time that this manuscript was written.126
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Figure 3: Randomized phase 2 trial of Regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. From Blood Adv.
2017;1(20):1645-9. Used with permission.

c.

Targeting inflammation
Regadenoson. In SCA patients there is increase in
the number of activated Invariant Natural Killer T
(iNKT) cells. Regadenoson is an A2A receptor agonist
that reduces the iNKT cells activation and thus
decreases inflammation (Figure 3). It was developed
by CV Therapeutics, now Gilead Sciences, as an
adjunct in cardiac perfusion imaging. A Phase I study
in 27 adults with SCD showed a 48% decrease in
activation of iNKT cells compared to baseline after
Regadenoson was administered with no toxicities
identified.127 Randomized phase 2 trial of Regadenoson
for treatment of acute VOCs in SCD did not reduce
iNKT cell activation to a prespecified level when
administered to patients with SCD. Since iNKT cell
activation was not reduced, the benefit of iNKT cellbased therapies in SCD cannot be determined.128
Further studies may be needed.
NKTT-120 is an investigational drug developed by
NKT Therapeutics to treat the symptoms of SCA. It is
a humanized monoclonal antibody designed to target
iNKT cells. Preclinical studies showed rapid and
sustained iNKT cell depletion in adults with SCD after
the administration of NKTT-120. Depletion of iNKT
cells had no effect on other natural killer cells. The Tcell antibody response was not impaired in response to
a Keyhole Limped Hemocyanin (KLH) challenge.129
An open-label, multi-center, single-ascending-dose
study of NKTT120 to determine its pharmacokinetics,
pharmacodynamics and safety in patients with SCA in
the steady state showed rapid, specific and sustained
iNKT cell depletion without any toxicity or attributed
serious adverse events.130
Statins. The vascular injury seen in SCD has been
described to share similarities with that of
atherosclerosis. Statins decrease inflammation and
improve endothelial function in cardiovascular disease

and are under study in SCD. They slow the production
of cholesterol in the body that may build up on the
walls of the arteries and block blood flow to the heart,
brain, and other parts of the body. A pilot study of 26
patients treated with atorvastatin showed a dose-related
decrease in inflammatory biomarkers (C-reactive
protein and IL-6 levels) and increased NO metabolite
levels.131 A Phase II trial of atorvastatin to determine
its effect on blood vessels in patients with SCD was
first posted in November 2012. The primary hypothesis
is that endothelial dysfunction is an important
contributor to the pathophysiology of albuminuria in
SCD. The investigators propose that atorvastatin will
improve endothelial dysfunction, decrease levels of
soluble fms-like tyrosine kinase-1 (sFLT-1), and
decrease albuminuria in patients with SCD. The study
was completed on November 14, 2019. Results not
available yet.132
Zileuton. Sickle cell disease patients have elevated
levels of 5-lipoxygenase, a potent inflammatory
leukotriene. Zileuton, a specific inhibitor of 5lipoxygenase, is FDA approved for asthma. Beneficial
effects in the SCD animal model have led to a
completed Phase I trial in SCD. It showed that higher
dose of Zileuton was safely tolerated by SCD patients
with good compliance.133
N-acetylcysteine. N-acetylcysteine (NAC) is an
inexpensive amino acid derivative that replenishes
intracellular levels of the glutathione and it is the ratelimiting substrate for glutathione generation, an
important antioxidant with pleiotropic effects on
inflammation.134 NAC inhibits dense cell formation and
restores glutathione levels toward normal, which
enables the cell to fight damage from ROS. It was used
30 years ago as a mucolytic agent in cystic fibrosis and
asthma. In the oral and parenteral routes, it treats
acetaminophen toxicity. In pilot studies, the
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administration of NAC resulted in a reduction of
oxidative stress. A Phase II, double-blind, randomized
clinical trial was completed to determine the efficacy
of NAC in decreasing dense cell and irreversible sickle
cell formation and VOC episodes in SCD. NAC
inhibited dense cell formation, restored glutathione
levels toward normal and decreased VOC episodes.135
A Phase III trial is underway.136
Canakinumab. Canakinumab has already been
approved by the FDA in 2009 as ILARIS, an
interleukin-1β blocker indicated for the treatment of
Cryopyrin-Associated Periodic Syndromes (CAPS), in
adults and children 4 years of age and older including:
Familial Cold Autoinflammatory Syndrome (FCAS)
and Muckle-Wells Syndrome (MWS).137 Because of its
anti-inflammatory potential it is being considered in a
study to determine its efficacy, safety and tolerability
in pediatric and young adult patients with SCA.138
A recent presentation at the 2019 American Society
of Hematology annual meeting described a multicenter, randomized, parallel group, double-blind,
placebo-controlled trial that recruited patients with
SCA (HbSS or HbS/ß0thalassemia) with history of ≥2
major pain episodes/year, screening baseline detectable
pain (using pain e-diaries) and serum high sensitivity
CRP level ≥1.0 mg/L. Patients were randomized with
1:1 ratio to receive six monthly subcutaneous injections
of either canakinumab 300 mg (4 mg/kg for patients
≤40 kg) or placebo. The concurrent use of hydroxyurea
was a stratification factor at randomization. Outcomes
were measured at baseline and at weeks 4, 8, 12, 16, 20,
24, after which all patients moved to open label
canakinumab treatment for additional 6 months.
Interim analysis for futility and safety was
performed on the first 30 enrolled patients
(canakinumab, n=16; placebo, n=14), of whom 26
patients completed the Week 12 assessments
(canakinumab, n=14; placebo, n=12), and 13 patients
completed the Week 24 assessments. Enrolled patients
(median age 17 years, range 12-20; 19 males, 11
females) were evenly distributed in the arms of the
study. Results showed that Futility criteria were not
met and no canakinumab-associated safety issues were
identified in this first interim analysis. A second
interim analysis is pending.139
Ambrisentan. Ambriseentan (Letairis) is an
endothelin receptor antagonist which has already been
approved by the FDA in 2007 for the treatment of
pulmonary arterial hypertension (PAH) (WHO Group
1): To improve exercise ability and delay clinical
worsening. In combination with tadalafil to reduce the
risks of disease progression and hospitalization for
worsening PAH, and to improve exercise ability.
Preliminary data about its potential role in SCD
suggest that These data suggest that endothelin receptor
blockade is safe, well tolerated and has the potential to
impact various aspects of disease pathophysiology in

SCD.140-142
d. Targeting oxidative Injury
𝛼𝛼-Lipoic acid. Alpha-lipoic acid (ALA) is a potent
antioxidant that is employed in the treatment of several
diseases. It augments cellular stress response by
increasing the transcription of antioxidant genes,
decreasing NF-kB, and increasing glutathione synthesis.
Acetyl-l-carnitine is an essential nutrient that facilitates
the entry of long-chain fatty acids into the
mitochondria and decreases lipid peroxidation in tissue.
α-Lipoic acid and acetyl-L-carnitine have a synergistic
antioxidant effect.143 A recent Phase II trial combining
antioxidants enrolled 42 patients to determine whether
α-lipoic acid and acetyl-L-carnitine will lower systemic
inflammation in patients with SCD. This study is
complete; however, data is not available for review.144
In an open randomized trial ALA treatment protected
normal individuals from oxidative damage to lipids and
proteins. In SCD patients, the dose applied were not
effective to prevent the oxidative damage.145 Further
trials are not planned at the present.
e.

Targeting anti-coagulation
Rivaroxaban.
The direct oral anticoagulants
(DOACs) include Rivaroxaban. Investigational
therapies targeting multiple pathways are being studied
for the treatment of SCD. Rivaroxaban, an orally active
direct Factor-Xa inhibitor and serine protease inhibitor,
was FDA approved in the US as an anticoagulant for
prophylaxis and treatment in acute coronary syndromes,
cerebral ischemia, pulmonary embolism and venous
thrombosis. It is currently being evaluated in a Phase II
clinical trial in SCD to reduce inflammation,
coagulation and endothelial cell activation, and
improve microvascular blood flow in patients during
the non-VOC steady state.146
f.

Targeting vasodilatation.
Arginine. Arginine is depleted in hemolysis due to
the release of arginase and leads to decreased NO
formation. In SCD patients with pulmonary
hypertension, arginine supplementation increases
plasma NO and rapidly decreases pulmonary artery
pressure by 15%.147 A recent randomized, double-blind,
placebo-controlled study of high-dose arginine
supplementation in hospitalized SCD patients with
VOC was completed and found a > 56% reduction in
opioid use in patients receiving arginine compared with
controls.148 A Phase II, randomized trial in 38 children
showed a significant reduction in opioid use and lower
pain scores at discharge in those treated with arginine
in comparison to the placebo arm. There was no
significant difference in hospital length of stay and no
toxicity was noted.149 A study was completed in
children with SCD to evaluate the effectiveness of
arginine at increasing NO levels, improving RBC

www.mjhid.org Mediterr J Hematol Infect Dis 2020; 12; e2020010

Pag. 15 / 24

function and reducing hospitalizations and pain
medication use. This was done by measuring gardos
channel activity, mean corpuscular Hb concentration
(MCHC) and NO levels. There was only statistically
significant difference in low-dose arginine with
decreased MCHC versus placebo. Data is available but
has not been published.150 Other studies have been
completed and awaiting analysis and two are currently
recruiting.151-154
Inhaled NO. As mentioned before NO failed as a
therapeutic agent for hospitalized patients with SCD
and VOC.155 Interestingly, the use of inhaled NO in the
emergency department significantly reduced pain
scores compared with placebo (P < 0.02) at the end of
NO inhalation although both groups had similar
baseline pain scores.156,157 Moreover, NO has been
reported to reduces sickle Hb polymerization.158
PF 04447943 (Phosphodiesterase 9A Inhibitor). A
randomized, double-blinded, Phase 1b trial [159] at 18
centers in the U.S. and Europe evaluated the safety and
tolerability of PF-04447943 over 29 days in people
with stable SCD. Multiple doses of PF-04447943, with
or without HU, administered to patients with SCD were
generally
well
tolerated
and
showed
pharmacodynamics parameters suggestive of a
protective effect against vaso-occlusion. In addition,
possible biomarkers to measure efficacy for use in
future SCD studies were noted.160 Inhibition of PDE9A
is required to treat diseases that lower the level of
cGMP which, in turn, regulates signal transduction161
and mediates vasodilatation.
IMR-687 is a highly selective, potent inhibitor of
phosphodiesterase 9. It has a multimodal mechanism of
action that acts primarily on RBC and has the potential
to act on white blood cells, adhesion mediators and
other cell types that are implicated in SCD. Currently,
it is an open-label extension study in adult patients
with SCA who were previously participants in the
Phase 2a study titled "A Phase 2a, Randomized,
Double-Blind, Placebo-Controlled Study of IMR-687
in Adult Patients with SCA”.162 This open-label
extension study will evaluate the long-term safety and
tolerability of IMR-687 in adult SCA patients.
Exploratory long-term parameters will also be
examined.
Riociguat is used in a Phase 2 multi-center,
randomized, double-blind, placebo-controlled, parallel
groups study aimed to evaluate its safety, tolerability
and efficacy compared with placebo in patients with
SCD.163
Olinciguat is use in the STRONG SCD in patients
with SCD. The primary aim of the study is to evaluate
the safety and tolerability of different dose levels of
Olinciguat compared with placebo when administered
daily for approximately 12 weeks to patients with
stable SCD. Exploratory objectives include evaluation
of pharmacokinetic as well as evaluation of its effect

on symptoms of SCD, health-related quality of life, and
biomarkers of pharmacodynamic activity.164
g.

Targeting Polymerization
Voxelotor (OXBRYTA), previously known as
GBT440, has the potential to selectively bind to Hb,
and increase its affinity for oxygen. It also inhibits Hb
polymerization and prevents RBCS from becoming
deformed. This should restore normal RBC function
and oxygen delivery. It should also help reduce the risk
of VOCs caused by sickle cells blocking blood vessels.
Voxelotor is oral, once-daily drug that binds to the
α-chain of HbS, stabilizing the molecule in the R-state
conformation, which is known to interrupt HbS
polymerization.101,165,166
The
target
for
HbS
modification with voxelotor is 20%-30%. In phase 1/2
trials, Voxelotor inhibited HbS polymerization, RBC
sickling, and hemolysis, with a consequent increase in
Hb concentration, while also demonstrating an
acceptable safety profile and was well tolerated.167
Phases 1/2 completed and Phase 3 randomized,
placebo-controlled HOPE trial involving patients with
SCD, Voxelotor (1500 mg and 900 mg) significantly
increased and sustained Hb levels compared to placebo
and reduced markers of hemolysis. These findings are
consistent with inhibition of HbS polymerization and
indicate a disease-modifying potential. The secondary
endpoints pertaining to frequency of VOC,
hospitalization stay, etc. we’re not significantly
different from placebo. Moreover, exploratory post-hoc
trial showed that Voxelotor resolved or improved leg
ulcers in some patients. The new drug application
(NDA) for Voxelotor is currently under priority review
by the FDA which provides for a six-month review,
and has been assigned a Prescription Drug User Fee
Act (PDUFA) target action date of February 26, 2020.
Besides the HOPE trial, Voxelotor is being
considered for other future trials. These include the
following:
• Hemoglobin oxygen affinity modulation to inhibit
Hb S polymerization (HOPE-KIDS 2, GBT 440032) trial. The objective of this trial is to investigate
the effect of Voxelotor on Transcranial Doppler
(TCD) flow velocity in pediatric patients with SCD
with conditional TCD.
• Actigraphy improvement with Voxelotor (Active)
trial. The objective of this trial is to assess the
impact of Voxelotor on physical activity, sleep
quality, and overall patient wellbeing in individuals
with SCD. Part 1 of this trial will be a phase 4 openlabel, single-arm, within-subject comparison
followed by Part 2 trial which is a randomized
withdrawal placebo-controlled trial.
FT-4202 (PKR Activator). FT-4202 is a selective
RBC pyruvate kinase-R activator (PKR) to be used as a
modifying therapy for the treatment of SCD. Its
mechanism of action includes activating the RBC’s
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natural PKR activity to decrease 2,3-DPG levels which
results in shifting the oxygen dissociation curve to the
left causing Hb to hold on to oxygen molecules longer
to decrease RBC sickling. In addition, the downstream
action of FT-4202 increases ATP levels that provide
energy to RBCs health and survival. These effects
would increase Hb levels and possibly decrease the
frequency of VOCs.168,169
h.

Targeting Supplements
Niacin (Vitamin B3). Niacin is a drug that has been
used to increase high density cholesterol (HDL), the
“good cholesterol”. It improves the blood flow in
people with SCD.170
Niacin, a drug that has been used to increase HDL
(good cholesterol) levels, improves blood flow in
people without SCD. This study will see if it can do the
same in people with the disease.
Cholecalciferol (Vitamin D3).
About 98% of
patients with SCD have vitamin D deficiency, defined
as a 25-hydroxyvitamin D level (25(OH)D) less than or
equal to 20 ng/mL. As a result of low bone density,
patients may develop osteonecrosis, chronic
inflammation and related pain.171 Since vitamin
D regulates calcium levels and supports bone health, its
deficiency may worsen musculoskeletal health
problems already present in people with SCD.
However, a Cochrane review study showed that the
evidence for vitamin D3 supplementation in patients
with SCD is not of sufficient quality to guide clinical
practice. Evidence of vitamin D supplementation in
sickle cell disease from high quality studies is
needed.172
Conclusions. There has been tremendous advance in
our knowledge of the pathophysiology of sickle cell
vascular injury over the past decade resulting in new
therapeutic targets. The field is witnessing promising
translational studies hoping to replace or use with HU
as the primary pharmacologic therapy for patients with
SCD. This review includes therapies targeting
increases in fetal Hb and the complex pathways in
adhesion, inflammation, oxidative damage and
polymerization.
Hydroxyurea is an oral agent that has decreased
morbidity and mortality in adults and children with
SCA. It decreases recurrent VOCs, ACS and blood
transfusion requirements, and improves quality of life
mainly through increasing fetal Hb production. It is
inexpensive and potentially available worldwide. It is
cytotoxic, which may cause myelosuppression and its
carcinogenic effects are unknown and long-term
studies have failed to document this. Traditionally, it
has been. contraindicated in pregnancy and during
lactation due to potential teratogenicity. Recent
anecdotes and case reports indicated its safety during
pregnancy and lactation. Its role in pregnancy and

lactation is currently the subject of clinical trials. It
seems it should not be taken during the first two
trimesters of pregnancy.
L-glutamine is metabolized to glutamate, the
glutathione precursor, and preserves intracellular NAD,
which is necessary for glutathione recycling. Oral
supplementation of glutamine in SCD increases the
NAD redox potential and may improve sickle
erythrocyte adhesiveness. Oral glutamine was
developed by Emmaus Medical for the treatment of
short bowel syndrome and in SCA and β thalassemia. It
decreases the resting energy expenditure in children
with SCD. A multicenter Phase III trial of L- glutamine
supplementation in 230 children to prevent VOC is
completed Results showed that the median number of
pain crises over 48 weeks was lower among those who
received oral therapy with L-glutamine, administered
alone or with HU, than among those who received
placebo, with or without HU.
Decitabine is an attractive agent as it induced fetal
Hb with similar disadvantageous risk profile like HU
with potential myelosuppression, teratogenicity and
carcinogenicity. It is an already approved therapy for
myelodysplastic syndrome and acute myeloid leukemia,
conditions more prevalent in the elderly. It is being
evaluated in oral form and in combination therapy
currently and further testing is warranted in the
pediatric population. Unlike HU, its effect to increase
Hb F level occurs much sooner than that for HU. Nacetylcysteine has reached Phase III trials. It targets
inflammation. A combination with a fetal Hb-inducing
agent such as HU is a potential strategy to combat SCD.
Studies involving NO so far have been disappointing in
the sickle cell population. It is surprising that arginine
therapy. was more promising than NO since its role is
to increase NO. Nevertheless, this natural amino acid is
an ideal agent for a combination regimen.
In the sickle cell population, there are challenges
with clinical trial enrollment since it is a relatively rare
and clinically heterogeneous disease. A paradigm shift
in clinical trial design would improve outcome. Due to
the complex pathophysiology of the disease, clinical
trials targeting a multi-agent approach may be more
successful as in oncology where combination
chemotherapy regimens have been more efficacious.
Trial design in SCD over the past three decades has
historically incorporated all patients with SCA.
Recently, this
approach is being modified to reassess endpoints to
determine benefits in targeted phenotypes, including
quality-of-life measures and incorporating biomarkers
in patient selection.
In summary, our greater understanding of the
pathophysiology of SCD has led to many new targets
for drug therapy, and with a paradigm shift in clinical
trial design. We are in an exciting position to improve
care for the millions who suffer from SCD. It is very
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probable that in the near future we may witness new
trials to treat SCD that contain two or more drugs that
have different mechanism of action. My prediction is
that such trials may have acronyms such as FOC, FOV,

FOCV, etc. trials where F refers to a drug that
increases Hb F, O refers to an antioxidant drug, C
refers to anti-adhesion drug and V to antipolymerization drug or other possible combinations.
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